Clovis Oncology heralds a PARP victory in frontline ovarian cancer — does anyone really care much? - Endpoints News
4/1/2022 12:00:00 AM3 years 1 month ago
by John Carroll
by John Carroll
Early on Thursday, Clovis Oncology trumpeted positive Phase III data for their PARP player Rubraca in frontline maintenance care of ovarian cancer, outlining a much improved PFS rate compared to placebo. The small-cap stock price $CLVS, which was eviscerated …
Early on Thursday, Clovis Oncology trumpeted positive Phase III data for their PARP player Rubraca in frontline maintenance care of ovarian cancer, outlining a much improved PFS rate compared to plac… [+1523 chars]
full article...